杭州瑞奥生物医药

Ruiao Biopharma is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company leverages its proprietary R&D platform to design highly selective inhibitors targeting critical signaling pathways, including BTK, JAK1, and TYK2. Its lead candidate, RA-001, is a next-generation BTK inhibitor currently in Phase 2 clinical trials for the treatment of B-cell malignancies. Ruiao Biopharma is supported by leading healthcare investors and aims to deliver high-quality, differentiated medicines to address significant unmet medical needs globally. The company maintains integrated capabilities spanning drug design, preclinical evaluation, and clinical development.